Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiopulmonary resuscitation performed by off-duty medical professionals versus laypersons and survival from out-of-hospital cardiac arrest among adult patients.

Resuscitation·2019

Same author

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer.

Annals of surgical oncology·2019

Same author

[Food Poisoning by Ginkgo Seeds through Vitamin B<sub>6</sub> Depletion].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2019

Same author

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.

Journal of translational medicine·2019

Same author

Diffusion kurtosis imaging of endometrial carcinoma: Correlation with histopathological findings.

Magnetic resonance imaging·2019

Same author

Catheter-directed therapy for acute pulmonary embolism in children.

Cardiology in the young·2018

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.

Tomohiro Sasaki¹, Takeshi Hirota, Yuriko Ryokai

¹Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Japan.

Drug Metabolism and Pharmacokinetics

|April 23, 2011

Summary

Genetic variations in the multidrug resistance-associated protein 3 (MRP3) gene were identified, but showed no significant impact on MRP3 function or 4-MUG pharmacokinetics in humans.

More Related Videos

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1

Published on: May 27, 2016

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

Area of Science:

Pharmacogenomics
Molecular Biology
Biochemistry

Background:

Multidrug resistance-associated protein 3 (MRP3), encoded by ABCC3, is an ATP-binding cassette transporter crucial for basolateral efflux of various substrates into the bloodstream.
Understanding genetic variations in ABCC3 is essential for predicting drug disposition and response.

Purpose of the Study:

To identify genetic polymorphisms in the ABCC3 gene.
To investigate the functional impact of these polymorphisms on ABCC3 expression and MRP3 transporter activity.
To evaluate the association between ABCC3 genotypes and the pharmacokinetics of 4-methylumbelliferone glucuronide (4-MUG) in a human population.

Main Methods:

Identification of genetic variants in ABCC3 across three ethnic populations.
Luciferase reporter gene assays to assess transcriptional activity.
Quantitative measurement of ABCC3 mRNA levels in human liver samples.
Human pharmacogenomic study involving 4-MUG administration and pharmacokinetic analysis.

Main Results:

Sixty-one genetic variants were identified in ABCC3, including 17 novel variants, though most occurred at low frequencies.
A specific promoter variant (-1767G>A) significantly reduced transcriptional activity in vitro.
No significant decrease in ABCC3 mRNA levels was observed in human liver samples.
No association was found between ABCC3 promoter genotypes and the pharmacokinetics of 4-MUG.

Conclusions:

While ABCC3 genetic polymorphisms exist and some affect transcriptional activity in vitro, they do not appear to significantly alter ABCC3 mRNA expression in human livers or influence the pharmacokinetics of MRP3 substrates like 4-MUG.
This study provides initial insights into the pharmacogenomic impact of ABCC3 variations, but further research is warranted to fully elucidate their clinical relevance.